Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/Obesity

NCT07701005 · clinicaltrials.gov ↗

COMPLETED

Status

154

Enrollment

OTHER

Sponsor class

Conditions

Steatosis of Liver
Metabolic Liver Injury
Obesity
Overweight
Insulin Resistance

Interventions

DRUG: Semaglutide
DRUG: Tirzepatide

Sponsor

Goztepe Prof Dr Suleyman Yalcın City Hospital